SavedAdd your journal

Journals / Marmara Medical Journal / 2018 / Cilt: 31 - Sayı: 2

Management of catheter-related complications during intraperitoneal chemotherapy for ovarian cancer: Two case reports and review of the literature

Over kanserinde intraperitoneal kemoterapi esnasında gelişen katater ilişkili komplikasyonların yönetimi: İki olgu sunumu ve literatür derlemesi

Günsu KİMYON CÖMERT
Osman TÜRKMEN
Alper KARALOK
Derman BAŞARAN
Çiğdem TORUN KILIÇ
Sevgi KOÇ
Fulya KAYIKÇIOĞLU
Nurettin BORAN
Pages
88–93
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, we presented two cases with catheter-related

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this article, we presented two cases with catheter-related
📊
Key Findings & Data:In this article, we presented two cases with catheter-related
💡
Conclusion & Impact:In this article, we presented two cases with catheter-related
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Over kanseri · Intraperitoneal kemoterapi · Kateter ilişkili komplikasyon

Abstract

In this article, we presented two cases with catheter-related

Özet

Bu çalışmada, over kanseri tanısıyla sitoredüktif cerrahiyi takiben

🔖

Cite This Article

CÖMERT, G. K., TÜRKMEN, O., KARALOK, A., BAŞARAN, D., KILIÇ, Ç. T., KOÇ, S., KAYIKÇIOĞLU, F., BORAN, N. (2018). Management of catheter-related complications during intraperitoneal chemotherapy for ovarian cancer: Two case reports and review of the literature. Marmara Medical Journal, Cilt: 31 - Sayı: 2, 88–93. https://ajindex.com/articles/283858

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med 2009; 6:e1000114. doi: 10.1371/journal.pmed.1000114. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136:359- 86. doi: 10.1002/ijc.29210. Landrum LM, Java J, Mathews CA, et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 2013; 130:12-8. doi: 10.1016/j. ygyno.2013.04.001. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354(1):34-43. doi: 10.1056/NEJMoa052985. Tewari D, Java JJ, Salani R, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2015; 33:1460-6. doi: 10.1200/jco.2014.55.9898. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19:1001-7. doi: 10.1200/jco.2001.19.4.1001. Fujiwara K, Armstrong D, Morgan M, Markman M. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer 2007; 17:1-20. doi: 10.1111/j.1525-1438.2007.00809.x. National Cancer Institute. NCI clinical announcement in 2006: intraperitoneal chemotherapy for ovarian cancer Available from: [http://ctepcancergov/highlights/docs/clin_ annc_010506pdf]; Accessed 30/11/2017.
  2. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 1982; 5:649- 56. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996; 82:359-74.
  3. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335:1950-5. doi: 10.1056/nejm199612263352603. Markman M, Wa